{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:46:56Z","timestamp":1792684016475,"version":"4.5.0"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Whether the association of quantitative flow ratio (QFR)\u2013guided percutaneous coronary intervention (PCI) with long-term outcomes differs according to multivessel disease (MVD) status is uncertain.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess the association of QFR-guided vs angiography-guided PCI with 3-year outcomes according to MVD status.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n In this prespecified secondary analysis of the FAVOR III China randomized clinical trial, patients were screened across 26 centers in China from December 25, 2018, to January 19, 2020. Eligible participants were adults undergoing PCI for stable or unstable angina or for myocardial infarction (MI) occurring at least 72 hours before screening who had at least 1 lesion with 50% to 90% diameter stenosis in a vessel of 2.5 mm or larger. The analysis compared QFR-guided with angiography-guided PCI according to MVD status. MVD was defined by involvement of at least 2 epicardial vessels or the left main coronary artery. The primary analyses of the current prespecified secondary analysis were completed in October 2024.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Randomization 1:1 to QFR-guided PCI or angiography-guided PCI.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary end point of the FAVOR III China randomized clinical trial was 1-year major adverse cardiac events (MACE), defined as a composite of all-cause death, MI, and ischemia-driven revascularization. The current analysis evaluated 3-year MACE.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 3825 patients in the intention-to-treat population (mean [SD] age, 62.7 [10.0] years; 2699 [70.6%] male), 2066 (54.0%) had MVD. In the MVD cohort, MACE occurred in 124 of 1023 patients (12.1%) in the QFR-guided group and 188 of 1043 patients (18.1%) in the angiography-guided group (hazard ratio, 0.65; 95% CI, 0.52-0.81;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), driven by lower rates of MI and revascularization. In the non-MVD cohort, MACE occurred in 76 of 890 patients (8.6%) and 95 of 869 patients (11.0%), respectively (hazard ratio, 0.77; 95% CI, 0.57-1.04;\n P<\/jats:italic>\n \u2009=\u2009.09). The treatment \u00d7 MVD interaction was not statistically significant (\n P<\/jats:italic>\n \u2009for interaction =\u2009.35). The findings of landmark, per-protocol, competing-risk, sensitivity, and hierarchical win-ratio analyses were directionally consistent with the main findings.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this prespecified secondary analysis of a randomized clinical trial of patients undergoing PCI, QFR-guided PCI was associated with a lower 3-year MACE rate among patients with MVD; however, no significant interaction was observed between treatment effect and MVD status. These findings provide longer-term randomized evidence supporting QFR-guided PCI across MVD strata and warrant further confirmation.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT03656848<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.39926","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:30:39Z","timestamp":1792683039000},"page":"e2639926","source":"Crossref","is-referenced-by-count":0,"title":["Quantitative Flow Ratio\u2013 vs Angiography-Guided Percutaneous Coronary Intervention"],"prefix":"10.1001","volume":"9","author":[{"given":"Han","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Cardiology, Fuwai Hospital, National Clinical Research Center for Cardiovascular Diseases, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanpu","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fuwai Hospital, National Clinical Research Center for Cardiovascular Diseases, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changdong","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fuwai Hospital, National Clinical Research Center for Cardiovascular Diseases, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingang","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fuwai Hospital, National Clinical Research Center for Cardiovascular Diseases, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianglong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fujian Medical University Union Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengxing","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Shanghai Jiao Tong University Affiliated Sixth People\u2019s Hospital, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqing","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuebo","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanzhe","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Fourth Affiliated Hospital of China Medical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liansheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Jiangsu Provincial People\u2019s Hospital, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Wuhan Asia Heart Hospital, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhujun","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Medical Research and Biometrics Centre, National Center for Cardiovascular Diseases, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kefei","family":"Dou","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fuwai Hospital, National Clinical Research Center for Cardiovascular Diseases, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixian","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fuwai Hospital, National Clinical Research Center for Cardiovascular Diseases, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian\u2019an","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjian","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fuwai Hospital, National Clinical Research Center for Cardiovascular Diseases, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William F.","family":"Fearon","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine and Stanford Cardiovascular Institute, Stanford University, Stanford, California"},{"name":"Cardiology Section, VA Palo Alto Health Care System, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengxian","family":"Tu","sequence":"additional","affiliation":[{"name":"Biomedical Instrument Institute, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Escaned","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico San Carlos IDISSC, Complutense University of Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubin","family":"Qiao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fuwai Hospital, National Clinical Research Center for Cardiovascular Diseases, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fuwai Hospital, National Clinical Research Center for Cardiovascular Diseases, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg W.","family":"Stone","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"FAVOR III China Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zening","family":"Jin","sequence":"additional","affiliation":[{"name":"for the FAVOR III China Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yu","sequence":"additional","affiliation":[{"name":"for the FAVOR III China Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guosheng","family":"Fu","sequence":"additional","affiliation":[{"name":"for the FAVOR III China Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Zhou","sequence":"additional","affiliation":[{"name":"for the FAVOR III China Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yundai","family":"Chen","sequence":"additional","affiliation":[{"name":"for the FAVOR III China Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Pu","sequence":"additional","affiliation":[{"name":"for the FAVOR III China Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinkai","family":"Qu","sequence":"additional","affiliation":[{"name":"for the FAVOR III China Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Guo","sequence":"additional","affiliation":[{"name":"for the FAVOR III China Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaojun","family":"Zhang","sequence":"additional","affiliation":[{"name":"for the FAVOR III China Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[{"name":"for the FAVOR III China Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Pan","sequence":"additional","affiliation":[{"name":"for the FAVOR III China Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Mi","sequence":"additional","affiliation":[{"name":"for the FAVOR III China Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Ye","sequence":"additional","affiliation":[{"name":"for the FAVOR III China Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Cheng","sequence":"additional","affiliation":[{"name":"for the FAVOR III China Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongchong","family":"Huang","sequence":"additional","affiliation":[{"name":"for the FAVOR III China Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Guo","sequence":"additional","affiliation":[{"name":"for the FAVOR III China Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Xu","sequence":"additional","affiliation":[{"name":"for the FAVOR III China Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin B.","family":"Leon","sequence":"additional","affiliation":[{"name":"for the FAVOR III China Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay J.","family":"Kirtane","sequence":"additional","affiliation":[{"name":"for the FAVOR III China Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick W.","family":"Serruys","sequence":"additional","affiliation":[{"name":"for the FAVOR III China Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Wijns","sequence":"additional","affiliation":[{"name":"for the FAVOR III China Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Windecker","sequence":"additional","affiliation":[{"name":"for the FAVOR III China Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"issue":"26","key":"zoi261081r1","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1056\/NEJM199606273342604","article-title":"Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses.","volume":"334","author":"Pijls","year":"1996","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi261081r2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.114.002666","article-title":"Diagnostic accuracy of stress myocardial perfusion imaging compared to invasive coronary angiography with fractional flow reserve meta-analysis.","volume":"8","author":"Takx","year":"2015","journal-title":"Circ Cardiovasc Imaging"},{"issue":"36","key":"zoi261081r3","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC Guidelines for the management of chronic coronary syndromes.","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"issue":"9","key":"zoi261081r4","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines.","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"issue":"14","key":"zoi261081r5","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.jcin.2020.04.040","article-title":"The impact of coronary physiology on contemporary clinical decision making.","volume":"13","author":"Kogame","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"issue":"4","key":"zoi261081r6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jacc.2019.10.060","article-title":"Utilization and outcomes of measuring fractional flow reserve in patients with stable ischemic heart disease.","volume":"75","author":"Parikh","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"zoi261081r7","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.jcin.2014.03.004","article-title":"Fractional flow reserve calculation from 3-dimensional quantitative coronary angiography and TIMI frame count: a fast computer model to quantify the functional significance of moderately obstructed coronary arteries.","volume":"7","author":"Tu","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"issue":"25","key":"zoi261081r8","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1016\/j.jacc.2017.10.035","article-title":"Diagnostic accuracy of angiography-based quantitative flow ratio measurements for online assessment of coronary stenosis.","volume":"70","author":"Xu","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"zoi261081r9","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009603","article-title":"Diagnostic performance of in-procedure angiography-derived quantitative flow reserve compared to pressure-derived fractional flow reserve: the FAVOR II Europe-Japan Study.","volume":"7","author":"Westra","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"zoi261081r10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.119.008487","article-title":"Novel indices of coronary physiology: do we need alternatives to fractional flow reserve?","volume":"13","author":"De Maria","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"issue":"10317","key":"zoi261081r11","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1016\/S0140-6736(21)02248-0","article-title":"Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial.","volume":"398","author":"Xu","year":"2021","journal-title":"Lancet"},{"issue":"22","key":"zoi261081r12","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1016\/j.jacc.2022.09.007","article-title":"2-Year outcomes of angiographic quantitative flow ratio-guided coronary interventions.","volume":"80","author":"Song","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"10006","key":"zoi261081r13","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(15)00057-4","article-title":"Fractional flow reserve versus angiography for guidance of PCI in patients with multivessel coronary artery disease (FAME): 5-year follow-up of a randomised controlled trial.","volume":"386","author":"van Nunen","year":"2015","journal-title":"Lancet"},{"key":"zoi261081r14","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ahj.2020.02.015","article-title":"Quantitative flow ratio-guided strategy versus angiography-guided strategy for percutaneous coronary intervention: rationale and design of the FAVOR III China trial.","volume":"223","author":"Song","year":"2020","journal-title":"Am Heart J"},{"issue":"14","key":"zoi261081r15","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1056\/NEJMsm1605385","article-title":"Per-protocol analyses of pragmatic trials.","volume":"377","author":"Hern\u00e1n","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi261081r16","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/eurheartj\/ehr352","article-title":"The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities.","volume":"33","author":"Pocock","year":"2012","journal-title":"Eur Heart J"},{"issue":"3","key":"zoi261081r17","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa0807611","article-title":"Fractional flow reserve versus angiography for guiding percutaneous coronary intervention.","volume":"360","author":"Tonino","year":"2009","journal-title":"N Engl J Med"},{"issue":"20","key":"zoi261081r18","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1016\/j.jcin.2018.07.035","article-title":"Reclassification of treatment strategy with instantaneous wave-free ratio and fractional flow reserve: a substudy from the iFR-SWEDEHEART trial.","volume":"11","author":"Andell","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"issue":"19","key":"zoi261081r19","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1700445","article-title":"Use of the instantaneous wave-free ratio or fractional flow reserve in PCI.","volume":"376","author":"Davies","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi261081r20","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.jcin.2017.11.030","article-title":"Impact of routine invasive physiology at time of angiography in patients with multivessel coronary artery disease on reclassification of revascularization strategy: results from the DEFINE REAL study.","volume":"11","author":"Van Belle","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"issue":"2","key":"zoi261081r21","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1161\/CIRCULATIONAHA.113.006646","article-title":"Outcome impact of coronary revascularization strategy reclassification with fractional flow reserve at time of diagnostic angiography: insights from a large French multicenter fractional flow reserve registry.","volume":"129","author":"Van Belle","year":"2014","journal-title":"Circulation"},{"issue":"45","key":"zoi261081r22","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1093\/eurheartj\/ehv452","article-title":"Deferral vs. performance of percutaneous coronary intervention of functionally non-significant coronary stenosis: 15-year follow-up of the DEFER trial.","volume":"36","author":"Zimmermann","year":"2015","journal-title":"Eur Heart J"},{"issue":"1","key":"zoi261081r23","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41591-025-04132-5","article-title":"Fractional flow reserve-guided percutaneous coronary intervention versus medical therapy for stable coronary artery disease: long-term results of the FAME 2 trial.","volume":"32","author":"Collet","year":"2026","journal-title":"Nat Med"},{"issue":"15","key":"zoi261081r24","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.jcin.2018.05.029","article-title":"Safety of the deferral of coronary revascularization on the basis of instantaneous wave-free ratio and fractional flow reserve measurements in stable coronary artery disease and acute coronary syndromes.","volume":"11","author":"Escaned","year":"2018","journal-title":"jacc cardiovasc interv"},{"issue":"15","key":"zoi261081r25","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.4244\/EIJ-D-21-00176","article-title":"Outcomes of quantitative flow ratio-based percutaneous coronary intervention in an all-comers study.","volume":"17","author":"Zhang","year":"2022","journal-title":"EuroIntervention"},{"issue":"4","key":"zoi261081r26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2025.10.042","article-title":"Rationales behind physiology-guided revascularization: diagnostic impact of quantitative flow ratio in the FAVOR III China trial.","volume":"19","author":"Zhang","year":"2026","journal-title":"JACC Cardiovasc Interv"},{"issue":"3","key":"zoi261081r27","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jcin.2017.09.009","article-title":"Prognostic implication of functional incomplete revascularization and residual functional SYNTAX score in patients with coronary artery disease.","volume":"11","author":"Choi","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"issue":"9","key":"zoi261081r28","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.120.009232","article-title":"Prognostic impact of residual anatomic disease burden after functionally complete revascularization.","volume":"13","author":"Lee","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"issue":"3","key":"zoi261081r29","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1056\/NEJMoa1803538","article-title":"Five-year outcomes with PCI guided by fractional flow reserve.","volume":"379","author":"Xaplanteris","year":"2018","journal-title":"N Engl J Med"},{"issue":"39","key":"zoi261081r30","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1093\/eurheartj\/ehaf504","article-title":"Fractional flow reserve vs angiography to guide percutaneous coronary intervention: an individual patient data meta-analysis.","volume":"46","author":"Mangiacapra","year":"2025","journal-title":"Eur Heart J"},{"issue":"10465","key":"zoi261081r31","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(24)02175-5","article-title":"Quantitative flow ratio versus fractional flow reserve for coronary revascularisation guidance (FAVOR III Europe): a multicentre, randomised, non-inferiority trial.","volume":"404","author":"Andersen","year":"2024","journal-title":"Lancet"},{"issue":"20","key":"zoi261081r32","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"22","key":"zoi261081r33","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1001\/jama.2025.4347","article-title":"CONSORT 2025 Statement: Updated Guideline for Reporting Randomized Trials.","volume":"333","author":"Hopewell","year":"2025","journal-title":"JAMA"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2855700\/zhang_2026_oi_261081_1792081182.42467.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:30:41Z","timestamp":1792683041000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2855700"}},"subtitle":["A Secondary Analysis of the FAVOR III China Trial"],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.39926","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]}}}